Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
61 hedge funds and large institutions have $336M invested in Oyster Point Pharma, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 60 → 61 (+1)
1% more capital invested
Capital invested by funds: $331M → $336M (+$4.75M)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.3M |
| 2 |
BlackRock
New York
|
+$4.9M |
| 3 |
First Manhattan
New York
|
+$4.02M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$1.08M |
| 5 |
JP Morgan Chase
New York
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$5.49M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$2.23M |
| 3 |
RI
RTW Investments
New York
|
-$1.35M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.05M |
| 5 |
Millennium Management
New York
|
-$998K |
OYST Hedge Fund Activity: Q1 2021 in Review
61 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q1 2021, worth a combined $336M — up 1.4% from $331M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new OYST positions and 8 closed out — a net gain of 1 holder — while 16 added to existing stakes and 17 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $15.3M. The largest seller was Emerald Advisers, exiting entirely with an estimated $5.49M sold.
- 61 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q1 2021, up from 60 in Q4 2020.
- Funds reported $336M of Oyster Point Pharma, Inc. Common Stock stock for Q1 2021, up 1.4% quarter-over-quarter.
- 9 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +1 holder.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q1 2021 was Wellington Management Group, an estimated $15.3M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q1 2021 was Emerald Advisers, an estimated $5.49M sold.
Based on aggregated 13F filings for Q1 2021.